We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

111 hedge funds and large institutions have $1.09B invested in Avidity Biosciences in 2021 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

120% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 20

28% more capital invested

Capital invested by funds: $853M → $1.09B (+$241M)

17% more funds holding

Funds holding: 95 → 111 (+16)

5.52% more ownership

Funds ownership: 91.8% → 97.32% (+5.5%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
111
Holders Change
+16
Holders Change %
+16.84%
% of All Funds
1.94%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
24
Increased
44
Reduced
20
Closed
8
Calls
$204K
Puts
–
Net Calls
+$204K
Net Calls Change
+$204K

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$99M
2
APM
Avidity Partners Management
Texas
+$35.8M
3
RI
RTW Investments
New York
+$17.4M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$14.6M
5
EC
EcoR1 Capital
California
+$14.2M

Top Sellers

1
MCMC
Matrix Capital Management Company
New Hampshire
-$29.7M
2
Victory Capital Management
Victory Capital Management
Texas
-$22.5M
3
DM
Deerfield Management
New York
-$13.8M
4
HA
HHLR Advisors
Cayman Islands
-$10.5M
5
ACM
Alethea Capital Management
Washington
-$5.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$175M +$99M +4,553,579 +179%
RI
2
RTW Investments
New York
$118M +$17.4M +800,000 +20%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$94.4M +$9.55M +439,352 +13%
BlackRock
4
BlackRock
New York
$79.1M +$11.1M +512,411 +19%
EC
5
EcoR1 Capital
California
$68M +$14.2M +655,555 +31%
Federated Hermes
6
Federated Hermes
Pennsylvania
$61M +$11M +504,984 +26%
CAM
7
Cormorant Asset Management
Massachusetts
$53.3M -$1.45M -66,552 -3%
Vanguard Group
8
Vanguard Group
Pennsylvania
$47.8M +$14.6M +670,815 +53%
APM
9
Avidity Partners Management
Texas
$40.5M +$35.8M +1,645,000 New
State Street
10
State Street
Massachusetts
$35.2M +$1.87M +85,886 +6%
ACA
11
Avoro Capital Advisors
New York
$28.3M +$13.1M +605,000 +111%
BC
12
Boxer Capital
California
$27.6M – – –
ACM
13
Alethea Capital Management
Washington
$22.4M -$5.63M -259,180 -22%
PA
14
Perceptive Advisors
New York
$21.8M -$4.2M -193,210 -18%
Alkeon Capital Management
15
Alkeon Capital Management
New York
$21.5M – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$18.2M +$7.1M +326,589 +79%
Wellington Management Group
17
Wellington Management Group
Massachusetts
$15M +$3.08M +141,807 +30%
5VM
18
5AM Venture Management
California
$13.7M +$12.1M +555,555 New
OCA
19
Octagon Capital Advisors
New York
$11M – – –
RCM
20
RA Capital Management
Massachusetts
$10.4M +$9.21M +423,616 New
Northern Trust
21
Northern Trust
Illinois
$8.75M +$1.82M +83,960 +31%
Deutsche Bank
22
Deutsche Bank
Germany
$8.51M +$80.1K +3,686 +1%
Goldman Sachs
23
Goldman Sachs
New York
$8.48M +$3.27M +150,618 +78%
Charles Schwab
24
Charles Schwab
California
$6.98M +$3.05M +140,392 +98%
US Bancorp
25
US Bancorp
Minnesota
$6.31M +$5.54M +254,868 +18,205%
1
2 3 4 5

RNAM Hedge Fund Activity: Q3 2021 in Review

111 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2021, worth a combined $1.09B — up 28% from $853M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new RNAM positions and 8 closed out — a net gain of 16 holders — while 44 added to existing stakes and 20 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $99M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $29.7M sold.

  • 111 institutional investors held Avidity Biosciences (RNAM) as of Q3 2021, up from 95 in Q2 2021.
  • Funds reported $1.09B of Avidity Biosciences stock for Q3 2021, up 28% quarter-over-quarter.
  • 24 funds opened new Avidity Biosciences positions in Q3 2021 and 8 closed out, a net change of +16 holders.
  • The largest Avidity Biosciences buyer in Q3 2021 was T. Rowe Price Associates, an estimated $99M added.
  • The largest Avidity Biosciences seller in Q3 2021 was Matrix Capital Management Company, an estimated $29.7M sold.

Based on aggregated 13F filings for Q3 2021.